Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India | Zendy

Ajay Gogia | Zendy; S. V. S. Deo | Zendy; Dayanand Sharma | Zendy; R.K. Phulia | Zendy; Sanjay Thulkar | Zendy; Prabhat Singh Malik | Zendy; Sandeep Mathur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India

Author(s) -

Ajay Gogia,

S. V. S. Deo,

Dayanand Sharma,

R.K. Phulia,

Sanjay Thulkar,

Prabhat Singh Malik,

Sandeep Mathur

Publication year - 2019

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.18.00184

Subject(s) - medicine , breast cancer , biomarker , oncology , estrogen receptor , cancer , metastasis , progesterone receptor , cohort , lung cancer , triple negative breast cancer , brain metastasis , biochemistry , chemistry

Biomarker-estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ neu) -discordance plays an essential role in the management and prognosis of patients with metastatic breast cancer. Rates of discordance have been previously reported around 12% to 35%, 30% to 50%, and 5% to 15%, respectively, in Western literature. Data are sparse regarding the same from developing countries, such as India.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research